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Abstract
Local and systemic immunological changes following vaginal HIV-1 exposures are poorly characterized and may influence susceptibility to
infection. Therefore, we examined longitudinal mucosal, plasma cytokine profiles and viral-specific T-cell responses (vSTRs) before and during
weekly repeated low-dose SHIVSF162P3 viral challenges in six female pigtailed macaques, even in the absence of overt systemic infection. Following
a single viral challenge, induction of several cytokines was detected consistently in cervico-vaginal lavages (CVL). With additional exposure and
documented systemic infection, a hallmark of response profile was defined as peak levels in both CVL (MCP-1,MIP-1α, TNF-α, IL-1β, IL-1RA and
IL-8) and plasma cytokines (MCP-1, eotaxin and IL-1RA) in the macaques. In the periphery, vSTRs were observed within the first one or two viral
challenges, but prior to the detection of systemic infection in 5 /6 exposed pigtailed macaques. These findings provide valuable information regarding
mucosal HIV-1 infection that may benefit microbicide research and development.
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The majority of HIV infections occur through intravaginal
HIV-1 transmission resulting in an estimated 18 million women
living with HIV-1 worldwide. In this population, the cervico-
vaginal mucosal surface serves as the first site of HIV-1 en-
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Apart from vaccines, the development and use of topical micro-
bicide gels for preventing HIV transmission remains a state-of-
the-art prevention strategy that is being vigorously studied
(review in Lederman et al., 2006). Otten et al. have developed a
mucosal repeated low (RL)-dose challenge model in female
pigtailed and male rhesus macaques (Otten et al., 2000, 2005)
which makes use of repetitive low viral doses at the mucosal
surface to closely mimic typical HIV levels during exposure.
Recent studies using this animal model suggest that a variety of
anti-HIV intervention strategies can be successfully explored
(Otten et al., 2005; Subbarao et al., 2006; Kim et al., 2006;
Ellenberger et al., 2006; Wilson et al., 2006).
A main objective of this study was to characterize immuno-
logical events following repeated viral challenges and to identify
mucosal and systemic events that occur prior to systemic infec-
tion. All female pigtailed macaques were repeatedly exposed to
SHIVSF162P3 vaginally. Longitudinal cytokine profiles derived
from cervico-vaginal and plasma specimens, and immunologic
Fig. 1. Longitudinal plasma viremia (A) by quantitative RT-PCR and viral-specific
antibody responses (B) at baseline and following weekly vaginal challenges. P8P
(control 1) and 303 (control 2) were in the control group, FF2 (placebo 1) and P8X
(placebo 2) were in the placebo group, FH3 (DC-SIGN 1) and TE8 (DC-SIGN 2)
were in the DC-SIGN-treated group. In each of the 6 studied pigtailed macaques,
plasma viremia levels and viral-specific antibody responses were assessed in a
baseline sample prior to the onset of the challenge study and weekly thereafter
following vaginal challenges. Plasma vRNA levels are reported as log10 copies/ml.
Except for control 1 and DC-SIGN 1, systemic infection was accomplished in the
other four pigtailed macaques during the first 5 weeks of virus exposures. Numbers
of corresponding viral challenges are indicated below each studied week (A). The
number in parenthesis indicates the number of exposures required for systemic
infection. Assay sensitivity was 100 vRNA copies/ml.
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following repeated mucosal challenges. The mucosal and
peripheral immunological responses that occurred following
the mucosal challenges and upon subsequent infection are
documented.
We also conducted a pilot study examining potential efficacy
of recombinant dendritic cell-specific ICAM-3 grabbing non-
integrin (DC-SIGN) as a topical intervention in our repeated-
challenge model. Immature dendritic cells (DCs) in the mucosa
are among the first cells that capture HIV-1 and play a critical
role in the early step of HIV dissemination to CD4-positive cells
following sexual transmission (Cameron et al., 1992; Pope,
1998; Spira et al., 1996; Hu et al., 2000; Pope and Haase, 2003;
Steinman et al., 2003). One of the most important receptors on
DCs involved in capturing HIV-1 is the C-type lectin DC-SIGN(also known as CD209). DC-SIGN binds to HIV-1 surface
glycoprotein gp120 and mediates direct transfer of HIV-1 to
CD4 T-cells (Geijtenbeek et al., 2000a,b; Gurney et al., 2005;
Kwon et al., 2002; van and Geijtenbeek, 2003). The pilot study
was conducted with 6 female macaques that received rDC-SIGN
gel, a placebo gel (hydroxyl-ethyl cellulose, HEC), or no product
(N=2 in each arm), to determine whether DC-SIGN could block
viral transmission or delay systemic infection following repeated
vaginal exposures. Although a protective role of topical DC-
SIGN could not be established here due to the low number of
animals used, the application of DC-SIGN may have altered
mucosal and systemic immunologic responses to viral challenge.
Therefore, further investigation into the role of DC-SIGN in
protecting against viral challenge through vaginal exposure is
warranted.
Results
Systemic infection following repeated low-dose viral challenges
and efficacy of exogenous DC-SIGN against infection
Systemic infection was achieved in all four animals in the
control and HEC placebo groups with 3 of 4 macaques showing
peripheral viremia after receiving 4 or fewer intravaginal
challenges (median of 3 challenges). One pigtailed macaque in
the control group, however, required more than 14 challenges to
achieve infection (Fig. 1A). In general, peak viremia, at a range
of 106–108 viral copies/ml, was seen within 1 week of initial
vRNA detection andwas followed by a gradual decline of vRNA
as previously observed (Otten et al., 2005; Kim et al., 2006).
Proviral DNA in PBMCs was first detected at the point of initial
viremia and remained steady after established infection (data not
shown). The virus-specific antibody response showed the first
EIA-positive result between week 2 and week 5 following the
first vRNA detection (average of 3.5 weeks post vRNA positive)
and was sustained throughout the course of this study (Fig. 1B).
Efficacy of rDC-SIGN as a topical product to prevent infection
was also evaluated in this pilot study involving 2 additional
animals. One DC-SIGN-treated pigtailed macaque became
infected following 5 viral challenges while the other animal
remained uninfected after 12 intravaginal challenges with top-
ical DC-SIGN applied prior to each inoculation. Furthermore,
after a rest period of 2 months and subsequent 6 re-challenges
without rDC-SIGN application, this latter animal remained
uninfected suggesting some level of natural resistance. None-
theless, due to the small numbers of animals treated with DC-
SIGN in this study and the differing results obtained from the
two animals used, conclusions regarding efficacy of DC-SIGN
cannot be made or at best indicate that DC-SIGN was not
efficacious in this pilot study.
Cytokine profile in CVL following repeated weekly challenge:
induction of cervico-vaginal cytokines following the first vaginal
challenge and peak induction at the onset of systemic infection
To determine the impact of mucosal viral exposure prior to
systemic infection, the levels of 19 cytokines were studied
494 N. Promadej-Lanier et al. / Virology 375 (2008) 492–503longitudinally from CVL samples collected at baseline and
every 2 weeks during the weekly repeated challenges. At 1 week
following the first vaginal challenge (week 2 samples), all five
macaques that remained uninfected displayed inductions of
multiple cytokines (Fig. 2A) indicating a direct influence of viral
exposure at the mucosa. We also observed that in general, fol-Fig. 2. A) Induction of cervico-vaginal cytokines and chemokines following one muc
challenge. Induction values on Y-axis were calculated from dividing the pg/ml leve
separates levels with or without induction. Data from placebo 2 (P8X) that became vR
cytokines/chemokines over baseline levels in the CVL following one mucosal challen
pigtailed macaques. Student's T-test P-value was 0.038 from comparison between the
within the control/placebo and DC-SIGN-treated animals respectively. C) Longitud
weekly challenges. CVL samples were collected biweekly. Arrows indicate the wee
cytokines/chemokines was seen at the same week or within 1 week from first vRNA
pigtailed macaques is shown.lowing one viral challenge (prior to infection), the magnitude of
cytokine induction in the CVL was higher in the control and
placebo groups when compared to DC-SIGN-treated macaques
(P=0.038) (Fig. 2B). These cytokines were also measured in the
CVL at the point of systemic infection and many of these
cytokines increased to their peak levels during the first week ofosal challenge. Week-2 CVL samples were collected at 24 h prior to the second
l of each cytokine at week 2 by its level from a baseline sample. Dashed line
NA positive at week 2 were not plotted. B) Difference between fold inductions of
ge in control/placebo treated pigtailed (all 4 animals) vs. both DC-SIGN-treated
two groups. The two bars represent the mean level of 53 and 11 fold inductions
inal observation of CVL cytokines and chemokines at baseline and following
k of the first plasma vRNA positive signal. It is noted that peak level of several
detection. Selected group of chemokines sharing similar patterns from these 4
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andMIP-1α all showed induction at week 2, which peaked at the
time of first vRNA detection then rapidly declined thereafterFig. 3. A) Longitudinal levels of IFN-γ, IL-1β, IL-17 andMIP-1α in the plasma from
IFN-γ, IL-1B, IL-17 andMIP-1α, at 150, 166, 40 and 19 times higher, respectively, t
of plasma MCP-1, IL-1RA and eotaxin as a hallmark of first plasma vRNA detectio
indicates the week of first viral RNA positive. Positive and negative values indica
these animals.(Fig. 2C). Several other cytokines, especially IL-8 and IL-1RA,
were also observed to have increased levels in CVL around the
time of first plasma viremia (data not shown). These patternsall six animals. Control 2, a resistant pigtailed macaque, consistently displayed
han the median levels observed in the other 5 studied macaques. B) Peaked level
n. Data from the remained uninfected DC-SIGN 1 were not plotted. 0 on X-axis
te the number of weeks before and after the week of first vRNA detection in
Fig. 4. A) Longitudinal viral-specific T-cell responses at baseline and weekly following repeated challenges with SHIVSF162P3 at 10 TCID50 in control 1 (P8P),
placebo 1 (FF2), placebo 2 (P8X) and DC-SIGN 2 (TE8). B) DC-SIGN 1 (FH3) and control 2 (303). Each bar graph represents T-cell responses specific for Gag, Nef,
Tat, Vif, Vpr or Rev proteins. For control 2 (303), data are shown for weeks 1, 3, 4, and 5 of the challenge study as well as weeks 22 (15th challenges) and 25 (18th
challenges, at one week post infection). Data from weeks 2 and 24 were not available due to insufficient amount of PBMC in these samples. Error bars in both A and B
represent the standard deviation from triplicate wells. Arrow at the bottom of the Y-axis indicates the time of first vRNA detection in each macaque. ND indicates that
the assay was not done. DC-SIGN 1 (FH3) showed no vRNA over the studied period. Control 2 (303) had first positive vRNA at week 24, following 17 viral
challenges. C) Proportion of virus-specific T-cell responses to each individual protein, Gag, Nef, Tat, Vif, Vpr and Rev at prior to the first vRNA detection (left charts)
and following vRNA positive detection (right charts). For each animal, the total magnitude from all the viral protein responses was normalized to 100 and the
percentage of the response to each protein was calculated accordingly.
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Fig. 4 (continued ).
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fected (data not shown).
Cytokine profile in plasma following repeated weekly challenge:
peak induction of MCP-1, eotaxin, and IL-1RA at the time of first
vRNA detection
Unlike that observed in mucosal samples, an overt induction
of cytokines following one viral challenge was not observed in
the periphery. In general, plasma levels of most cytokines tested
remained quite stable following the first few viral challenges and
throughout the remainder of the study regardless of the point of
infection. As shown in Fig. 3A, plasma levels of 4 representative
cytokines remained largely unchanged from baseline with onecontrol showing consistently higher levels. However, peak
levels of plasma MCP-1, eotaxin, and IL-1RAwere observed to
coincide with the first point of vRNA detection (Fig. 3B).
Further analysis between the levels of these cytokines and the
magnitude of plasma viremia showed no significant correlations
(data not shown).
Dynamics of virus-specific T-cell responses following viral
exposure prior to systemic infection
To investigate whether this mucosal repeated-challenge
regimen resulted in detectable cellular responses in the peri-
phery prior to systemic infection, PBMCs from all six macaques
were tested for virus-specific T-cell responses as measured by
IFN-γ ELISPOT. Among the animals that became infected
following less than 6 exposures, 3 of 4 animals developed low-
level SIV specific T-cell responses after one or two viral chal-
lenges and prior to the detection of viral RNA in the plasma or
proviral DNA in PBMCs, indicating an early activation of
these specific T-cells in the periphery (Fig. 4A). The fourth
animal became infected after only 2 exposures and showed
evidence of T-cell responses at that point (Fig. 4A). The 2
animals that received the greatest number of challenges
showed markedly disparate T-cell response profile. One animal
(DC-SIGN 1) developed T-cell responses following the first
mucosal challenge and maintained these responses during
subsequent challenges but never developed a systemic
infection during the challenge period, while the other animal
(control 2) developed no virus-specific T-cell responses during
the prolonged challenge period prior to infection(Fig. 4B). In
the majority of these macaques, responses to early viral
proteins Tat and Rev, but not Nef, predominated following
the first few mucosal challenges and prior to plasma vRNA
detection.
Dynamics of viral-specific T-cell responses in acute infection
following repeated challenges
Although cellular responses prior to systemic infection were
predominately against Tat and Rev, specific responses follow-
ing vRNA detection were directed towards other viral proteins
including the emergence of Nef-specific T-cells. In all animals
that became infected, we observed a change in the hierarchy of
the immunodominant responses following infection (Fig. 4C).
As expected, the magnitude and breadth of the responses were
high upon acute viral infection and throughout the remainder of
the study among animals in control and placebo groups. How-
ever, following infection, DC-SIGN 2 appeared to have lower
magnitude and breadth of vSTRs than the other animals; median
total magnitude of 243 and 1136 SFU/106, (Pb0.0005), median
breadth of 2 vs. 4 (Pb0.0005) for the DC-SIGN2 and control/
placebo respectively. Finally, to examine the possible role of
virus-specific T-cell responses in viral control, the correlation
between plasma viral load and the viral-specific T-cells re-
sponses was examined. Using data from control and placebo
treated macaques infected before 6 exposures, a reverse corre-
lation between Nef and Rev-specific responses and vRNA was
Fig. 5. Linear regression analysis for the correlation between Nef-specific T-cell responses and plasma viral load derived from the same samples (left panel) and
between Rev-specific T-cell responses and plasma viral RNA (right panel). Each plot represents the correlative value between plasma viral load and Nef/Rev-specific
T-cell responses for a given animal at a particular time point. Data were collected for each animal from the first week of vRNA detection and at any following weeks
when data were obtainable. The analysis includes results from macaques in the control/placebo group (excluding control 2). Significant inverse correlations between
Nef and viral level and between Rev and viral level were noted (P=0.0006 and 0.0040 for Nef and Rev respectively).
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and Ref respectively) (Fig. 5).
Discussion
The current understanding of immunologic outcomes fol-
lowing mucosal exposure in the repeated-challenge model still
remains incomplete. Our present findings identify immunologic
events subsequent to intravaginal exposures prior to and fol-
lowing systemic infection at the mucosa and in periphery using
the macaque model.
Mucosal cytokine induction following repeated viral challenges
prior to systemic infection
Upon mucosal exposure, immediate host antiviral immune
responses may be critical to preventing viral dissemination be-
yond the local tissues. In this study, several mucosal cytokines
were induced upon initial mucosal exposures to SHIV162P3 and
prior to detectable systemic infection. Although some cytokines
are also regulated by the menstrual cycle (e.g. IL-6 and IL-8)
(Al-Harthi et al., 2000, 2001), the cytokine pattern we observed
following virus challenges was uniform among the animals
studied. It seems most likely that this initial induction is due to
the action of a major host innate immune system such as Toll-
like receptors (TLR) which are abundantly expressed at the
mucosa and have been observed to trigger the production of
cytokines upon exposure to a broad range of pathogens (review
in Takeda et al., 2003). Recently, in support of our findings,
dendritic cells and macrophages were reported to produce pro-
inflammatory and regulatory cytokines in response to ssRNA
from HIV-1 and influenza viruses via TLR recognition (Heil
et al., 2004; Diebold et al., 2004). While it is likely that the
observed induction of cytokines in the CVL following the first
viral challenges may serve as the first line of defense by innate
immune system in this model, the opposite effect from proin-
flammatory cytokines in facilitating viral transmission is also
possible.Peak levels of mucosal and plasma cytokines during the first
plasma vRNA detection
We also observed that coinciding with the first plasma vRNA
detection, several cytokines were induced at their highest levels at
the site of initial virus exposure (Fig. 2C). Peak levels of these
cytokines (e.g.,TNF-α, IL-1B, MCP-1 and MIP-1α) were also
detected in the CVL suggesting that this was the greatest period of
antigen stimulation, potentially due to local viral replication. In
the plasma, the first vRNA detection was marked by peak levels
of MCP-1, eotaxin and IL-1RA. These same cytokines were also
among those in the CVL that appeared at their highest levels over
this period (data not shown). The association between peak levels
of MCP-1, eotaxin and IL-1RA in the plasma and acute viral
infection is not unexpected. The roles of MCP-1 and eotaxin in
immune cell recruitment following infection or viral replication
have been previously demonstrated (Vicenzi et al., 2000; Culley
et al., 2006). Furthermore, genes for MCP-1 and eotaxin are
localized on the same chromosomal regions linked to a role in
enhancing HIV-1 transmission (Modi et al., 2003). In addition,
Rimaniol et al. (1996) noted that the level of IL-1RAwas elevated
in the plasma of HIV-1-infected subjects compared to control
subjects, a finding also supported by our current data in non-
human primate models. In vitro, it was found that production of
IL-Ra was triggered by the Env protein at the early step of HIV
infection (Zavala et al., 1995), while in a human study, increasing
concentrations of plasma IL-1RAwas found to correlate withHIV
progression (Kreuzer et al., 1997).We also observed significantly
higher levels of several plasma cytokines in a control animal that
showed marked resilience to infection, as compared with other
study animals (Fig. 3A). Therefore, in addition to other potential
mechanisms, these plasma cytokines may be innate host factors
attributing to its resistance to SHIV infection in this model.
vSTRs following repeated viral challenges, prior to vRNAdetection
It remains unclear if repeated exposures to virus induce pro-
tective immunity to subsequent challenges, as observed in HIV-1
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2001; Fowke et al., 2000; Sriwanthana et al., 2001; Promadej
et al., 2003). While low-level HIV-specific responses were often
present in these reported HEPS subjects, a recent study utilizing
a group of SIV-exposed uninfected rhesus macaques found no
association between virus-specific immunity (cellular and
humoral) and resistance to mucosal transmission (Letvin et al.,
2007). In the present study, the detected viral-specific T-cell
responses (vSTRs) that persistently appeared earlier following
the first few mucosal challenges did not result in protection from
subsequent viral challenges. Another repeated-challenge study
utilizing SIVmac251 reported a sporadic appearance of either T-
cell proliferation or low-level Gag specific responses during a
period of occult infection, prior to the period of persistent
viremia (Ma et al., 2004). The presence of peripheral vSTRs
prior to detection of plasma vRNAwas observed in 3 of the four
animals that became infected by week six (control 1, placebo 1
and DC-SIGN 2) (Fig. 4A). While it is possible that the first
detected vSTRs at week 2 prior to the first vRNA detection (at
week3) in the placebo 1 animal (FF2) were present due to
nascent infection, it is just as likely that the responses observed
were the same as those observed for control 1(P8P) and DC-
SIGN 2 (TE8) and were only questionable based on how quickly
plasma vRNA appeared in this animal. Nevertheless, even
discounting the results for placebo 1 (FF2), the observations
made pertaining to vSTRs in P8P and TE8 prior to systemic
infection in this repeated-challenge model are of interest. We
also note that DC-SIGN 1(FH3), the resistant animal, showed a
low level of plasma vRNA at week one. However, as the
detected vRNA at this time point was at the limit of detection and
no further vRNA was detected nor was proviral DNA ever
detected in that animal, the persistent detection of vSTR through
week 20 (Fig. 4B, data not shown after week 6) was most likely
not due to this observed blip of vRNA.
In our study, early vSTRs seen in the periphery before the
detection of plasma vRNA were dominated by T-cells with
specificity to the early viral regulatory proteins, Tat and Rev.
Although an association between Tat and Rev responses and
viral control in HIV-1 studies has been noted (Zagury et al.,
1998; van Baalen et al., 1997), these early low-level T-cell re-
sponses were apparently not sufficient to confer protection from
successful transmissions under the exposure conditions we have
employed. Low-level T-cell responses detected following the
first few viral challenges, however, provide further evidence that
virus exposure to host immune components at the mucosa can
subsequently activate systemic immune responses prior to
systemic infection. Moreover, these vSTRs in the periphery
may reflect the same T-cell activation that occurs at the
secondary lymph nodes, as observed in an SIV model which
showed similar T-cell specificity from both the periphery and the
secondary lymph nodes (Kuroda et al., 2000). Recently, a study
conducted using low doses of the X4-tropic SHIVSF33A strain
for intravaginal inoculation identified a number of exposed
seronegative (ES) macaques (Tasca et al., 2007). In contrast to
the findings of Letvin et al., virus-specific cellular and pro-
liferative responses in the periphery, as well as robust viral-
specific proliferative responses in lymphoid tissues and gut,were observed in several of these ES macaques. The viral-
specific T-cell responses in these ES macaques support our
observation that vSTRs could develop and be detected following
viral exposures and in the absence of systemic infection.
Plasma viremia and vSTRs following acute infection
Following infection from weekly SHIV162P3 challenges, we
observed initial peak viremia and vRNA set points which were
similar to those observed in both repeated and single high-dose
challenge studies (Otten et al., 2005; Kim et al., 2006; Harouse
et al., 2001; Hsu et al., 2003, 2005; McDermott et al., 2004; Pahar
et al., 2007; Tsai et al., 2007). In addition, rather broad and high
magnitude T-cell responses to several SIV proteins, including
Gag, were observed in several infected macaques, similar to those
reported previously for SIVmac239, SHIVSF33A and SHIVSF162P3
infection (McDermott et al., 2004; Pahar et al., 2007; Trunova
et al., 2006). Viral-specific T-cell responses may have influenced
the plasma viral load decline observed in infected control and
placebo macaques in this study. Furthermore, the inverse corre-
lation between Nef and Rev-specific responses and the corre-
sponding levels of plasma vRNA (Fig. 5) implied relevant roles
for these specific T-cells toward viral control. These observations
are supported by previous findings suggesting that cellular im-
mune responses against early viral proteins such as Nef and Rev
may have a critical role in suppressing viral replication (Yang
et al., 2003; van Baalen et al., 2002). However, some investigators
observed a positive relationship between virus-specific T-cells
and viral load, which was believed to be a result of virus repli-
cation driving T-cell expansion (Betts et al., 2001). Since a similar
analysis has not been done in the other repeated model studies, a
possible role ofNef andRev-specific T-cells in viral control in this
model requires further investigation.
DC-SIGN treatment: mucosal and systemic immunological
observations
Although a protective role of topical DC-SIGN for preventing
viral transmission was not observed in part due to the small
numbers of animals receiving DC-SIGN treatment, our data
suggest that DC-SIGN application may affect subsequent immu-
logical responses in this model and warrants further study. For
example, despite a similar vRNA level, total T-cell responseswere
substantially lower in the DC-SIGN-treated macaque that became
infected than those in mock-treated or placebo treated macaques
(Fig. 4A, weeks 7 to 16 data not shown). Since the initial duration
and amount of antigen encountered have been shown to influence
the magnitude of the T-cell responses (Prlic et al., 2006; Kaech
andAhmed, 2001), it is possible, although not conclusive, that the
lowered responses may be the result of altered immune system
recognition of viral antigens following rDC-SIGN treatment.
Moreover, DC-SIGN-treated pigtailed macaques showed a
significantly lower level of cytokine induction when compared
to control animals (Fig. 2B). This could be due to DC-SIGN
binding to surface glycoprotein on the challenge viruses, thereby
greatly reducing viral antigenic exposure to both innate (such as
Toll-like receptor) and adaptive immune factors. If true then, the
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nitude of early proinflammatory responses at the mucosa and
possibly altering the T-cell response profile. It is alsoworth noting
that the persistent lack of infection in one DC-SIGN-treated pig-
tailed macaque was similar to the findings in exposed uninfected
macaques which appeared protected even after a series of higher
challenge doses (Letvin et al., 2007). DC-SIGN treatment may
have effectively reduced the infectious titre of the innoculum and
provided the opportunity for protective responses to manifest and
later become evident upon subsequent challenges even in the
absence of DC-SIGN treatment. However, further study using
larger numbers of animals will be needed before these obser-
vations can be addressed.
In conclusion, repeated-exposure approaches were used to
establish infection in non-human primates as a rational model to
mimic human sexual exposure. The data provided in this report
following repeated mucosal challenge of female pigtailed ma-
caques gave insight into themucosal and systemic immunological
events that precede and follow successful SHIV transmission.
This information further supports the use of repeated-exposure
models, as the model allows not only the study of immune corre-
lates of natural resistance to infection but also the examination of
immulogical events that take place following viral challenges
prior to systemic infection.
Materials and methods
Macaques
Six normal cycling mature female pigtailed macaques
(Macaca nemestrina) which were aged N4 years and weighed
5–8 kg were included in the study. These macaques tested
negative for simian immunodeficiency virus (SIV), simian re-
trovirus and simian T-cell leukemia virus. All macaques were
housed under Biosafety level 2. All macaque studies adhered to
the Guide of the Care and Use of Laboratory Animals (Institute
for Laboratory Animal Research, 1996) and all animal pro-
cedures were approved by the Centers for Disease Control and
Prevention Animal Care and Use Committee. Blood was
collected in CPT (B.D., San Jose, CA) or ACD (B.D. San
Jose, CA) tubes. Whole blood samples were collected into CPT
tubes weekly. Cervico-vaginal samples were collected prior to
the commencement of the study to obtain baseline levels and
were also collected biweekly thereafter at 24 h prior to each
vaginal challenge. One baseline sample per animal was
analyzed. Two pigtailed macaques which were given no product
were assigned as control (P8P and 303), two were given placebo
(FF2 and P8X) and two were in the DC-SIGN-treated group
(FH3 and TE8). Macaques in the placebo group received the
“universal” placebo, hydroxyl-ethyl cellulose (HEC) (Particle
Sciences, Inc.) while the DC-SIGN group was treated with DC-
SIGN 20 min prior to viral challenge.
DC-SIGN
The entire extracellular portion of recombinant human
soluble DC-SIGN spanning amino acid 59–404 was expressedand purified via insect cell expression systems. The purified
soluble DC-SIGN59–404 was then formulated in hydroxyl-ethyl
cellulose vehicle at a concentration of 0.4 mg/ml for topical
application (Jia and Butera, personal communication). This
recombinant soluble DC-SIGN in HEC was applied to two
pigtailed macaques vaginally. DC-SIGN-treated macaques were
subsequently challenged at 20 min following gel application.
DC-SIGN treatment was stopped following infection.
Viruses and RL vaginal challenges
Stock culture of SHIVSF162P3, a CCR5-using strain was
acquired from the National Institutes of Health AIDS Research
and Reference Program (originated from Cheng-Mayer et al.
Luciw et al., 1995; Harouse et al., 2001) and propagated on
pigtailed macaque PBMCs to derived a new stock which has
been previously described (Otten et al., 2005). For the viral
challenge in this study, 1 ml of diluted SHIV SF162P3 stock
equivalent to 10TCID50 (approximately 10
6 vRNA copies) was
inoculated intravaginally on each animal. The same stock was
used in all weekly challenges in these 6 macaques throughout
the study.
Weekly RL challenges were provided using 10 TCID50
SHIVSF162P3. The six macaques were divided into 3 groups; two
for DC-SIGN treatment who received 2 ml of DC-SIGN per
inoculation, two for placebo treatment who received 2 ml HEC
per inoculation and 2 for control group who received no treat-
ment. Weekly vaginal viral challenges were performed using
1 ml of cell-free viral stock as previously described (Otten et al.,
2005). Systemic infection here is defined by the first vRNA
detection in the plasma with a positive proviral DNA in the
PBMCs. In the DC-SIGN-treated and placebo groups, viral
challenges were done after 20 min following DC-SIGN and
HEC application. Baseline and weekly blood collections for
viral load determination were done at each 12 challenges. In
macaques that remained uninfected following 12 challenges, a
2 month rest period was applied and followed by up to 6 re-
challenges without DC-SIGN treatment. Virus exposures were
stopped once vRNA was detected in the plasma.
Quantitation of plasma viral RNA and proviral DNA in
peripheral blood
Quantitation of plasma viral RNA (vRNA) was achieved by
an in-house real-time polymerase (gag) gene PCR-based viral
load assay as described previously (Subbarao et al., 2006).
Tagman real-time 5′ nuclease techniques were used for quan-
titation of cell associated proviral DNA which was used as a
confirmatory assay for systemic infection as described pre-
viously (Otten et al., 2005).
Virus-specific antibody responses
Antibody responses (IgG and IgM against gp120, gp36 and
p24) were measured using a standard EIA system (Bio-Rad
Genetic Systems EIA, Redmond, WA) as previously described
(Otten et al., 2005).
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Simultaneous detection of multiple soluble cytokines and
chemokines in plasma and CVL collected from all macaques
was achieved utilizing luminex bead technology.Multiplex bead
kits were purchased from the following five manufacturers:
BioSource International, Inc. (Camarillo, CA, USA; for IFNγ,
IL-2, TNF-β, IL-1β, IL-6, IL-17, MCP-1, MIP-1α, RANTES,
IL-2R and eotaxin), Bio-Rad Laboratories, Inc. (Hercules, CA,
USA; forG-CSF,GM-CSF,MIP-1β, and IL-7), LINCOResearch,
Inc. (St. Charles, MO, USA; for IL-4 kit), R&D Systems, Inc.
(Minneapolis, MN, USA; for IL-1RA kit), and Upstate Labora-
tories, Inc.(East Syracuse, NY; for IL-8 and TNF-β). 11-mutiplex
assay includes beads and detection antibodies listed above from
BioSource International, Inc. 8-multiplex assay includes the
cytokine antibody beads and biotinylated antibodies for G-CSF,
GM-CSF, MIP-1α, IL-7, IL-8, TNF-α, IL-1RA, and IL-4. Each
cytokine bead solution was diluted to 5000 beads per tested well.
Detection antibodies were diluted as recommended by each
manufacturer or modified as necessary. A similar internal positive
control from supernatant of PMA/ionomycin stimulated pigtailed
PBMCs was used in all the cytokine luminex runs throughout the
study. In the CVL, cytokine analysis excluded any data of IL-2,
IL-4 and IL-17 where their levels were uniformly below the
detection limit.
Cellular immune responses by IFN-γ ELISPOT
Freshly isolated macaque PBMCs were used within 4 hr of
collection. IFN-γ ELISPOT assays were done using PBMCs
collected at baseline and weekly for 12 weeks. Determination of
virus-specific T-cell responses was done using pools of 15-mers
with a 15-amino acid overlap of SIVmac239 Gag, Nef, Vpr, Vif,
Tat and Rev from NIH AIDS research and reagent program
(Bethesda, MD). A pool of peptides was made for each protein to
achieve the final concentration of 0.2 μg/ml for each individual
peptide. ELISPOT assay was performed as follows. In brief,
multiscreen-HA plates (Millipore, MA) were coated with antihu-
man interferon-γ monoclonal antibody (5 μg/ml, 100 μl/well,
clone B27; BD Bioscience). Pigtailed PBMCs (200,000 cells/
well) were incubated with each pool of peptides on anti- IFN-γ
coated wells overnight. Incubations with anti-biotinylated IFN-γ
antibody (1 μg/ml, Mabtech, Cincinnati, OH; 2 h), strepavidin-
HRP (1 μg/ml, BD Bioscience, San Jose, CA; 1 hour) and
NovaRED™ substrate (Vector lab, Burlingame, CA)were applied
sequentially for colored spot development as recommended by
manufacturer. Spots were enumerated using an AID reader (Cell
Technology, Inc, Maryland). Gag, Nef, Tat, Rev, Vif or Vpr
specificity was presented as the mean number of spots per 106
PBMCs. A response is considered positive when the following
two criteria aremet: 1) a specific SFU/10 6 PBMCs of greater than
50; and 2) a specific index over the background of greater than 2.
Statistical analysis
Difference between parameters or groups of subjects was
determined using 2 tailed T-test. Correlation between two pa-rameters was determined using 2-variable linear regression
analysis. R2 and P-value for each measure of significance were
reported.
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